MNOV Relative Valuation
MNOV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MNOV is overvalued; if below, it's undervalued.
Historical Valuation
MediciNova Inc (MNOV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.50. The fair price of MediciNova Inc (MNOV) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.42
Fair
-3.40
PE
1Y
3Y
5Y
0.00
EV/EBITDA
MediciNova Inc. (MNOV) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 1.56. The thresholds are as follows: Strongly Undervalued below -12.80, Undervalued between -12.80 and -5.62, Fairly Valued between 8.74 and -5.62, Overvalued between 8.74 and 15.92, and Strongly Overvalued above 15.92. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.29
EV/EBIT
MediciNova Inc. (MNOV) has a current EV/EBIT of -1.29. The 5-year average EV/EBIT is -3.77. The thresholds are as follows: Strongly Undervalued below -10.91, Undervalued between -10.91 and -7.34, Fairly Valued between -0.20 and -7.34, Overvalued between -0.20 and 3.37, and Strongly Overvalued above 3.37. The current Forward EV/EBIT of -1.29 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
MediciNova Inc. (MNOV) has a current PS of 0.00. The 5-year average PS is 35.06. The thresholds are as follows: Strongly Undervalued below -129.49, Undervalued between -129.49 and -47.21, Fairly Valued between 117.34 and -47.21, Overvalued between 117.34 and 199.62, and Strongly Overvalued above 199.62. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
MediciNova Inc. (MNOV) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.24. The thresholds are as follows: Strongly Undervalued below -23.89, Undervalued between -23.89 and -14.06, Fairly Valued between 5.58 and -14.06, Overvalued between 5.58 and 15.41, and Strongly Overvalued above 15.41. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.95
P/FCF
MediciNova Inc. (MNOV) has a current P/FCF of -2.95. The 5-year average P/FCF is -6.07. The thresholds are as follows: Strongly Undervalued below -18.78, Undervalued between -18.78 and -12.43, Fairly Valued between 0.28 and -12.43, Overvalued between 0.28 and 6.63, and Strongly Overvalued above 6.63. The current Forward P/FCF of -2.95 falls within the Historic Trend Line -Fairly Valued range.
MediciNova Inc (MNOV) has a current Price-to-Book (P/B) ratio of 1.48. Compared to its 3-year average P/B ratio of 1.45 , the current P/B ratio is approximately 2.26% higher. Relative to its 5-year average P/B ratio of 1.66, the current P/B ratio is about -10.67% higher. MediciNova Inc (MNOV) has a Forward Free Cash Flow (FCF) yield of approximately -14.88%. Compared to its 3-year average FCF yield of -12.35%, the current FCF yield is approximately 20.50% lower. Relative to its 5-year average FCF yield of -10.27% , the current FCF yield is about 44.86% lower.
1.48
P/B
Median3y
1.45
Median5y
1.66
-14.88
FCF Yield
Median3y
-12.35
Median5y
-10.27
Competitors Valuation Multiple
The average P/S ratio for MNOV's competitors is 0.52, providing a benchmark for relative valuation. MediciNova Inc Corp (MNOV) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MNOV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MNOV in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MediciNova Inc (MNOV) currently overvalued or undervalued?
MediciNova Inc (MNOV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.50. The fair price of MediciNova Inc (MNOV) is between NaN to NaN according to relative valuation methord.
What is MediciNova Inc (MNOV) fair value?
MNOV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of MediciNova Inc (MNOV) is between NaN to NaN according to relative valuation methord.
How does MNOV's valuation metrics compare to the industry average?
The average P/S ratio for MNOV's competitors is 0.52, providing a benchmark for relative valuation. MediciNova Inc Corp (MNOV) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for MediciNova Inc (MNOV) as of Jan 08 2026?
As of Jan 08 2026, MediciNova Inc (MNOV) has a P/B ratio of 1.48. This indicates that the market values MNOV at 1.48 times its book value.
What is the current FCF Yield for MediciNova Inc (MNOV) as of Jan 08 2026?
As of Jan 08 2026, MediciNova Inc (MNOV) has a FCF Yield of -14.88%. This means that for every dollar of MediciNova Inc’s market capitalization, the company generates -14.88 cents in free cash flow.
What is the current Forward P/E ratio for MediciNova Inc (MNOV) as of Jan 08 2026?
As of Jan 08 2026, MediciNova Inc (MNOV) has a Forward P/E ratio of -3.40. This means the market is willing to pay $-3.40 for every dollar of MediciNova Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for MediciNova Inc (MNOV) as of Jan 08 2026?
As of Jan 08 2026, MediciNova Inc (MNOV) has a Forward P/S ratio of 0.00. This means the market is valuing MNOV at $0.00 for every dollar of expected revenue over the next 12 months.